Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
46
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,570.90 | 30.80 | -0.36% |
CAC 40 | 8,154.51 | 31.93 | 0.39% |
DAX 40 | 22,287.56 | 27.09 | -0.12% |
Dow JONES (US) | 43,428.02 | 748.63 | -1.69% |
FTSE 100 | 8,659.37 | 3.60 | -0.04% |
HKSE | 23,477.92 | 900.94 | 3.99% |
NASDAQ | 19,524.01 | 438.36 | -2.20% |
Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
S&P 500 | 6,013.13 | 104.39 | -1.71% |
S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
SSE Composite Index | 3,379.11 | 28.33 | 0.85% |